Home Companies Catalysts Deep Dives
Moizerto difamilast APPROVED
Drug Profile
ModalitySmall molecule
RouteTOPICAL
Therapy AreaImmunology
Launch2022-06-01
Peak Sales Est$200M
Formulations[{"id":"moizerto-topical","route":"TOPICAL","device":"Ointment (0.3%, 1%)","setting":"PATIENT_SELF",
Companies
4578 (ORIGINATOR)100%
Mechanism: PDE4 inhibitor (oral)
Expert: Oral small molecule inhibitor of phosphodiesterase 4 (PDE4). Elevates intracellular cAMP, modulating cytokine production (TNF-alpha, IL-23, IL-17).
Everyday: Blocks an enzyme (PDE4) inside immune cells that controls inflammation. By inhibiting this enzyme, it reduces the inflammatory signals that cause skin plaques and joint swelling.
Targets: ["PDE4"]
Programs (1)
IndicationStageKey StudyRegional Status
Atopic DermatitisAPPROVEDPhase 3 Japan[{"stage":"APPROVED","region":"JAPAN","approval_date":"2022-06-01"}]
Notes
Otsuka-discovered. First topical PDE4i in Japan. Non-steroidal. Japan only. US rights licensed to Medimetriks.
Data from Supabase · Updated 2026-03-24